Daiichi-Sankyo Company Limited

Daiichi Sankyo Company, Limited was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. 
 
      

View in Other Languages

News

Asian Markets Overview of December 9

🕔12/9/2009 1:30:25 PM 20398

US stocks fell on Tuesday on disappointing corporate news and renewed worries over global credit markets. Asian stocks mostly opened lower today with Australian and Japanese markets slashed sharply at opening.

Read Full Article

Australian Market Report of March 30: A Slowdown after Weeks of Rallies

🕔3/30/2009 1:00:53 PM 16289

The Australian share closed slightly higher lifted by miners. The benchmark S&P/ASX200 index ended the day up 0.7%, or 25.7 points, at 3672.3, while the broader All Ordinaries index rose 0.8%, or 29.3 points, at 3615.6. For the week, the ASX200 added 6% and the All Ordinaries rose 6.2%.

Read Full Article

Biota Holdings Limited (ASX:BTA) Daiichi-Sankyo (TYO:4568) Exercise Right To Market CS-8958 In Japan

🕔3/30/2009 9:41:03 AM 9027

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that Daiichi Sankyo (TYO:4568), the co-owner of the long acting neuraminidase inhibitor (LANI) CS-8958, has signed a contract to manufacture and market the product in Japan, pending the successful completion of the pivotal Phase III clinical studies and on obtaining registration approval. Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market.

Read Full Article

Asian Market Overview of January 23

🕔1/23/2009 3:00:04 PM 18366

Tokyo stocks opened sharply lower Friday with investor sentiment hurt by Sony Corp.'s forecast of an annual operating loss as well as by a fall in U.S. shares overnight due to disappointing corporate earnings there. Yesterday the Aisan markets gained on the good lead from Wall Street. Hong Kong's Hang Seng Index firmed 0.6% to 12657.99. The Shanghai Composite Index added 1%. South Korea's Kospi Composite rose 1.1% to 1116.23.

Read Full Article

Australian Market Report of January 22: Helped by Short Selling Ban

🕔1/22/2009 1:00:28 PM 17449

Yesterday the Australian stock market ended the day lower, led by financial stocks, on renewed worries about banking industry worldwide. The benchmark S&P/ASX200 index was down 1%, or 33.8 points, at 3442.8, while the broader All Ordinaries index was lower by 0.9%, or 30.2 points, at 3394.8. Regulator ASIC's move to extend a ban on covered short-selling of financial securities would give a positive lead to the banking industry.

Read Full Article

Biota Holdings Limited (ASX:BTA) LANI Phase III Clinical Trials Set For Enrolment

🕔11/17/2008 12:02:03 PM 11702

Biota Holdings Limited (ASX:BTA)(PNK:BTAHY) today announced that the multiple centres involved in the Phase III clinical trail on its long acting neuraminidase inhibitor (LANI) CS-8958 are ready to commence treatment. Patients are expected to enrol into the study progressively throughout the Asian influenza season.

Read Full Article

Biota Holdings Limited (ASX:BTA) LANI Phase II completed - Phase III scheduled

🕔7/31/2008 9:41:18 AM 6551

Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints. The initial Phase III trial is scheduled to commence later this year. CS-8958 is a long acting neuraminidase inhibitor (LANI), and is co-owned with Daiichi-Sankyo Company Limited (TYO:4568).

Read Full Article
###

115,904 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 34) (Last 30 Days: 121) (Since Published: 18494) 

Company Data

    Headquarters
  • 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo
    103-8426, Japan
  • Telephone
  • 81-3-6225-1111 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.daiichisankyo.co.jp